OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143

BACKGROUND: Despite available treatment options for patients (pts) with recurrent glioblastoma (GBM), < 5% of pts survive 5 years beyond initial diagnosis, and no single-agent therapy has demonstrated a survival benefit in the second-line setting, including bevacizumab (bev), which is approved fo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Reardon, D. A., Omuro, A., Brandes, A. A., Rieger, J., Wick, A., Sepulveda, J., Phuphanich, S., de Souza, P., Ahluwalia, M. S., Lim, M., Vlahovic, G., Sampson, J.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
ORAL PRESENTATIONS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5463583/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.071
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars